Live Breaking News & Updates on Fudan University Huashan Hospital|Page 6

Stay updated with breaking news from Fudan university huashan hospital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pandemic could mark 'turning point' for Chinese science | Science


Science’
s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.
On 2 January 2020, a group of clinician-researchers at the Jinyintan Hospital here, along with colleagues at other institutions, launched a study of 41 patients suffering from a new, atypical pneumonia. The team assembled clinical data, laboratory results, and chest x-rays; tracked the production of immune system molecules called cytokines; and noted the use of antivirals, antibiotics, and corticosteroids. Thirteen of the patients required intensive care, and six died.
The group’s observations, published online by
The Lancet on 24 January 2020, were the first dispatch from the clinical front lines of the COVID-19 pandemic and gave clinicians around the world a detailed picture of what to brace for as the virus, then called 2019-nCoV, began to race across the globe. The paper also contained a clear warning: “We are concerned that 2019-nCoV could have acquired ....

Union Hospital , United States , United Arab Emirates , New Zealand , New South Wales , Harvard University , Chen Jianguo , John Haupt , Nick Wilson , Donald Trump , Elsevier Scopus , Chaolin Huang , Edward Holmes , Wang Weibing , Xihong Lin , Chaolong Wang , Tongji Chaolong Wang , Jenny Lee , Shi Zhengli , Zhang Wenhong , Dennis Normile , Researchers At Huazhong University Of Science , University Of Sydney , University Of Otago , Heising Simons Foundation , Huazhong University Of Science ,

Pandemic could mark 'turning point' for Chinese science


Medical workers take care of a COVID-19 patient at Union Hospital in Wuhan, China, in April 2020.
PHOTO: XINHUA/SHEN BOHAN/GETTY IMAGES
On 2 January 2020, a group of clinician-researchers at the Jinyintan Hospital here, along with colleagues at other institutions, launched a study of 41 patients suffering from a new, atypical pneumonia. The team assembled clinical data, laboratory results, and chest x-rays; tracked the production of immune system molecules called cytokines; and noted the use of antivirals, antibiotics, and corticosteroids. Thirteen of the patients required intensive care, and six died.
The group s observations, published online by
The Lancet on 24 January 2020, were the first dispatch from the clinical front lines of the COVID-19 pandemic and gave clinicians around the world a detailed picture of what to brace for as the virus, then called 2019-nCoV, began to race across the globe. The paper also contained a clear warning: “We are concerned that ....

United States , New Zealand , New South Wales , Harvard University , United Arab Emirates , Chen Jianguo , John Haupt , Nick Wilson , Donald Trump , Elsevier Scopus , Chaolin Huang , Edward Holmes , Wang Weibing , Xihong Lin , Chaolong Wang , Tongji Chaolong Wang , Jenny Lee , Shi Zhengli , Zhang Wenhong , Heising Simons Foundation , Sinovac Biotech , Fudan University Huashan Hospital , National Natural Science Foundation Of China , Researchers At Huazhong University Of Science , University Of Sydney , Pulitzer Center ,

Beijing Mandates Millions to Get China-Made COVID-19 Vaccine Shots Despite Still Undergoing Testing


Beijing Mandates Millions Must Get China-Made COVID-19 Vaccine as Testing Continues
The Chinese regime recently mandated that 50 million doses of COVID-19 vaccines must be administered to people designated as high risk by Feb. 15, 2021 although drug companies have yet to complete testing and the vaccines have yet to be approved by regulators.
Meanwhile, Fosun Pharmaceutical announced that it had ordered 100 million doses of the COVID-19 vaccine developed by German drug company BioNTech, which will arrive in China in 2021. BioNTech has partnered with Pfizer to supply vaccines for the U.S. and EU markets, which were approved by their respective regulators, but the vaccine developed for the China market is still in Phase II trial. ....

Hong Kong , Tao Lina , Zhang Wenhong , Sinovac Biotech , Fudan University Huashan Hospital Department , China National Health Commission Zeng Yixin , Shanghai Center , Chinese Academy Of Sciences , Health Times , China International Fair For , Products Institute On Dec , Academy Of Military Medical Sciences , Fosun Pharmaceutical , Military Medical Sciences , Chinese Academy , Times Photo , Getty Images , State Council , National Health Commission Zeng Yixin , Disease Control , Fudan University Huashan Hospital , China International Fair , Jiangsu Province , Beijing Biological Products Institute , ஹாங் காங் , தாவோ லினா ,